Why Natera’s Diakonos Oncology collaboration matters for ctDNA-guided cancer drug development
Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
What the TRACERx study reveals about Personalis’ MRD technology in NSCLC
Personalis, Inc. has reported pivotal findings from its NeXT Personal assay in a new Cell publication, highlighting the test’s ability to detect molecular residual disease in stage I to III non-small cell lung cancer. The study, part of the TRACERx initiative and led by Professor Charles Swanton of the Francis Crick Institute and University College
Medical Devices & Diagnostics
Exact Sciences unveils key Oncodetect results in TNBC: Is this a reimbursement turning point?
Exact Sciences Corporation has presented first-time clinical results for its Oncodetect molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC), showcasing a strong correlation between circulating tumor DNA (ctDNA) detection and recurrence risk following neoadjuvant therapy and surgery. The results, drawn from a 147-patient cohort in the NSABP B-59 substudy, were unveiled at